Table 1.
PK parameters obtained from quantification of therapeutic-dose ciprofloxacin (400 mg given intravenously over 1 hour) with liquid chromatography–tandem mass spectrometry (cohort A)
| Cohort A | tmax (h) | Cmax (µg/mL) | AUC ((µg/mL).h) | t1/2 (h) | CL (L/h) | Vss (L) |
|---|---|---|---|---|---|---|
| Plasma | 1.00 (0.50–1.00) | 4.15 (3.47–4.96) | 9.93 (8.58–11.50) | 4.22 (3.01–5.90) | 33.70 (28.38–40.02) | 177.3 (139.9–224.7) |
| Subcutaneous tissue | 2.00 (2.00–2.00) | 0.95 (0.57–1.56) | 3.52 (2.10–5.91) | – | – | – |
| ELF | 2.00 | 1.68 | 5.36 | – | – | – |
| AUC ratios | AUCST/AUCplasma | 0.36 | ||||
| AUCELF/AUCplasma | 0.54 |
tmax is reported as median with range in parentheses and all other PK parameters are reported as geometric mean with 95% confidence interval in parentheses (n = 9 for plasma, n = 8 for subcutaneous tissue). For ELF, the 95% confidence interval is not given as only one timepoint per subject was measured and concentrations from three subjects per timepoint were averaged
AUC area under the concentration–time curve (from 0 to 10 h for plasma and from 0 to 8 h for subcutaneous tissue and ELF), AUCELF/AUCplasma ratio of AUC in ELF to AUC in plasma, AUCST/AUCplasma ratio of AUC in subcutaneous tissue to AUC in plasma, CL apparent total body clearance of ciprofloxacin from plasma, Cmax maximum concentration, ELF epithelial lining fluid, PK pharmacokinetic, t1/2 elimination half-life, tmax time to maximum concentration, Vss apparent volume of distribution at steady state